Top

Published in:

01-12-2013 | Original Paper

Association of HLA alleles and haplotypes with vitiligo in Moroccan patients: a case–control study

Authors: Abdellatif Bouayad, L. Benzekri, S. Hamada, C. Brick, B. Hassam, M. Essakalli

Published in: Archives of Dermatological Research | Issue 10/2013

Abstract

The aim of this study was to identify HLA class II alleles that may be involved in vitiligo genetic susceptibility in the Moroccan population and to determine susceptible and protective HLA alleles/haplotypes in vitiligo. One-hundred unrelated vitiligo patients and 300 healthy unrelated controls were studied for HLA class II alleles by polymerase chain reaction-sequence-specific primers. The phenotypic frequency of DRB1*07 (OR = 2.23, p _c = 0.014) was significantly higher, while that of DRB1*03 (OR = 0.40, p _c = 0.014) was significantly lower in patients than in controls. Haplotype DRB1*07–DQB1*02 (OR = 2.25, p _c = 0.024) was positively associated with vitiligo patients, while haplotype DRB1*03–DQB1*02 (OR = 0.35, p _c = 0.012) was negatively associated with this group. Vitiligo patients with positive family history and negative anti-thyroid peroxidase antibody (anti-TPO) have an extremely high phenotype frequency of DRB1*07–DQB1*02 haplotype (OR = 2.91, p _c = 0.048 and OR = 2.62, p _c = 0.00475, respectively). DRB1*03–DQB1*02 (OR = 0.32, p _c = 0.048 and OR = 0.38, p _c = 0.048, respectively) was negatively associated with patients without a family history and negative anti-TPO. This study demonstrated the positive association of HLA class II alleles and haplotypes with vitiligo in the Moroccan population. There may be differences in HLA haplotypes distribution in patients according to family history and anti-TPO profile.

Al Badri AM, Foulis A, Todd PM, Gariouch JJ, Gudgeon JE, Stewart DG, Gracie JA, Goudie RB (1993) Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 169:203–206PubMedCrossRef

Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16:208–214PubMedCrossRef

Birlea SA, Ahmad FJ, Uddin RM, Ahmad S, Pal SS, Begum R, Laddha NC, Dwivedi M, Shoab Mansuri M, Jin Y, Gowan K, Riccardi SL, Holland PJ, Ben S, Fain PR, Spritz RA (2013) Association of Generalized Vitiligo with MHC Class II Loci in Patients from the Indian Subcontinent. J Invest Dermatol 133:1369–1372PubMedCrossRef

Birlea SA, Gowan K, Fain PR, Spritz RA (2010) Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. J Invest Dermatol 130:798–803PubMedCrossRef

Buc M, Fazekasová H, Cechová E, Hegyi E, Kolibásová K, Ferencík S (1998) Occurrence rates of HLA-DRB1, HLA-DQB1, and HLA-DPB1 alleles in patients suffering from vitiligo. Eur J Dermatol 8:13–15PubMed

Daneshpazhooh M, Mostofizadeh GM, Behjati J, Akhyani M, Robati RM (2006) Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 6:3PubMedCrossRef

de Vijlder HC, Westerhof W, Schreuder GM, de Lange P, Claas FH (2004) Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res 17:270–274PubMedCrossRef

Dominguez-Soto L, Hojyo-Tomoka T, Vega-Memije E, Arenas R, Cores-Franco R (1994) Pigmentary problems in the tropics. Dermatol Clin 12:777–784PubMed

Dunston GM, Halder RM (1990) Vitiligo is associated with HLA-DR4 in black patients. Arch Dermatol 126:56–60PubMedCrossRef

10.

Excoffier L, Laval G, Schneider S (2007) Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 1:47–50PubMed

11.

Fain PR, Babu SR, Bennett DC, Spritz RA (2006) HLA class II haplotype DRB1*04–DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset. Pigment Cell Res 19:51–57PubMedCrossRef

12.

Finco O, Cuccia M, Martinetti M, Ruberto G, Orecchia G, Rabbiosi G (1991) Age of onset in vitiligo: relationship with HLA supratypes. Clin Genet 39:48–54PubMedCrossRef

13.

Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K, Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists, Clinical Standards Department, Royal College of Physicians of London, Cochrane Skin Group, Vitiligo Society (2008) Guideline for the diagnosis and management of vitiligo. Br J Dermatol 159:1051–1076PubMedCrossRef

14.

Gibert M, Reviron D, Mercier P, Chiaroni J, Boetsch G (2000) HLA-DRB1 and DQB1 polymorphisms in Southern France and genetic relationships with other Mediterranean populations. Hum Immunol 61:930–936PubMedCrossRef

15.

Gomez-Casado E, del Moral P, Martínez-Laso J, García-Gómez A, Allende L, Silvera-Redondo C, Longas J, González-Hevilla M, Kandil M, Zamora J, Arnaiz-Villena A (2000) HLA genes in Arabic-speaking Moroccans: close relatedness to Berbers and Iberians. Tissue Antigens 55:239–249PubMedCrossRef

16.

Grimes PE, Halder RM, Jones C, Chakrabarti SG, Enterline J, Minus HR, Kenney JA Jr (1983) Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 119:300–303PubMedCrossRef

17.

Hegedüs L, Heidenheim M, Gervil M, Hjalgrim H, Høier-Madsen M (1994) High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 74:120–123PubMed

18.

Howitz J, Brodthagen H, Schwartz M, Thomsen K (1977) Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 113:47–52PubMedCrossRef

19.

Hu DY, Ren YQ, Zhu KJ, Lv YM, Cheng H, Zhang Z, Li Y, He SM, Tang J, Liu JL, Lin Y, Sun YY, Zuo XB, Chen G, Sun LD, Yang S, Zhang XJ (2011) Comparisons of clinical features of HLA-DRB1*07 positive and negative vitiligo patients in Chinese Han population. J Eur Acad Dermatol Venereol 25:1299–1303PubMedCrossRef

20.

Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Bennett DC, Herbstman DM, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouary T, Ezzedine K, Geel N, Lambert J, Overbeck A, Spritz RA (2011) Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol 131:1308–1312PubMedCrossRef

21.

Kemp EH (2004) Autoantibodies as diagnostic and predictive markers of vitiligo. Autoimmunity 37:287–290PubMedCrossRef

22.

Kemp EH, Wasterman EA, Weetman AP (2001) Autoimmune aspects of vitiligo. Autoimmunity 34:65–77PubMedCrossRef

23.

Kovacs SO (1998) Vitiligo. J Am Acad Dermatol 38:647–666PubMedCrossRef

24.

Laberge G, Mailloux CM, Gowan K, Holland P, Bennett DC, Fain PR, Spritz RA (2005) Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res 18:300–305PubMedCrossRef

25.

Le Poole IC, Das PK, Van den Wijngaard RM, Bos JD, Westerhof W (1993) Review of etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 2:145–153PubMedCrossRef

26.

Majumder PP, Nordlund JJ, Nath SK (1993) Pattern of familial aggregation of vitiligo. Arch Dermatol 129:994–998PubMedCrossRef

27.

Mehta NR, Shah KC, Theodore C, Vyas VP, Patel AB (1973) Epidemiological study of vitiligo in Surat area, South Gujarat. Indian J Med Res 61:145–154PubMed

28.

Metzker A, Zamir R, Gazit E, David M, Feuerman EJ (1980) Vitiligo and the HLA system. Dermatologica 160:100–105PubMedCrossRef

29.

Quan C, Ren YQ, Xiang LH, Sun LD, Xu AE, Gao XH et al (2010) Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 42:614–618PubMedCrossRef

30.

Ren Y, Yang S, Xu S, Gao M, Huang W, Gao T, Fang Q, Quan C, Zhang C, Sun L, Liang Y, Han J, Wang Z, Zhang F, Zhou Y, Liu J, Zhang X (2009) Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet 5:e1000523PubMedCrossRef

31.

Roitberg-Tambur A, Witt CS, Friedmann A, Safirman C, Sherman L, Battat S, Nelken D, Brautbar C (1995) Comparative analysis of HLA polymorphism at the serologic and molecular level in Moroccan and Ashkenazi Jews. Tissue Antigens 46:104–110PubMedCrossRef

32.

Shong YK, Kim JA (1991) Vitiligo in autoimmune thyroid disease. Thyroidology 3:89–91PubMed

33.

Singh A, Sharma P, Kar HK, Sharma VK, Tembhre MK, Gupta S, Laddha NC, Dwivedi M, Begum R; Indian Genome Variation Consortium, Gokhale RS, Rani R (2012) HLA alleles and amino-acid signatures of the peptide-binding pockets of HLA molecules in vitiligo. J Invest Dermatol 132:124–134

34.

Taştan HB, Akar A, Orkunoğlu FE, Arca E, Inal A (2004) Association of HLA class I antigens and HLA class II alleles with vitiligo in a Turkish population. Pigment Cell Res 17:181–184PubMedCrossRef

35.

Venkataram MN, White AG, Leeny WA, al Suwaid AR, Daar AS (1995) HLA antigens in Omani patients with vitiligo. Clin Exp Dermatol 20:35–37PubMedCrossRef

36.

Venneker GT, de Waal LP, Westerhof W, D’Amaro J, Schreuder GM, Asghar SS (1993) HLA associations in vitiligo patients in the Dutch population. Dis Markers 11:187–190PubMed

37.

Wang J, Zhao YM, Wang Y, Xiao Y, Wang YK, Chen HD (2007) Association of HLA class I and II alleles with generalized vitiligo in Chinese Hans in north China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24:221–223PubMed

38.

White AG, Lehny W, Kuchipudi P, Varghese M, Al Riyami H, Al Hashmi S, Daar AS (1999) Histocompatibility antigens in Omanis: comparison with other Gulf populations and implications for disease association. Ann Saudi Med 19:193–196PubMed

39.

Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, Cassiman JJ (2001) Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 145:90–94PubMedCrossRef

40.

Zhang XJ, Liu HS, Liang YH, Sun LD, Wang JY, Yang S, Liu JB, Gao M, He PP, Cui Y, Yang Q (2004) Association of HLA class I alleles with vitiligo in Chinese Hans. J Dermatol Sci 35:165–168PubMedCrossRef

Title: Association of HLA alleles and haplotypes with vitiligo in Moroccan patients: a case–control study
Authors: Abdellatif Bouayad
L. Benzekri
S. Hamada
C. Brick
B. Hassam
M. Essakalli
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 10/2013
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-013-1368-z

At a glance: The STEP trials

Springer Medicine

Association of HLA alleles and haplotypes with vitiligo in Moroccan patients: a case–control study

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2013

Study of small proline-rich proteins (SPRRs) in health and disease: a review of the literature

Psoriatic keratinocytes prime neutrophils for an overproduction of superoxide anions

Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of alopecia areata

Osteopontin and adiponectin: how far are they related in the complexity of psoriasis?

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study

Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation